Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

ClinicalTrials.gov ID: NCT02663674

Public ClinicalTrials.gov record NCT02663674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase IV randomized, double-blinded, placebo-controlled study in 1000 individuals aged 18 years or older, with community acquired pneumonia (CAP) who meet all eligibility criteria in endemic regions. This study is designed to provide data on the effectiveness of early antifungal treatment (Fluconazole, 400 mg/day) for coccidioidomycosis pneumonia (also referred to as Valley Fever (VF) Pneumonia or acute onset valley fever) vs. placebo in subjects with coccidioidomycosis pneumonia. Patients who are prescribed antibacterials by their health care provider for acute CAP will be randomized to receive either placebo or 400 mg/day of fluconazole for 42 days. The primary objective is to assess the clinical response of early empiric antifungal therapy with fluconazole at Day 22 in subjects with coccidioidomycosis pneumonia and are compliant with the study intervention.

Study identification

NCT ID
NCT02663674
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Enrollment
72 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2015
Primary completion
Jun 20, 2018
Completion
Jul 30, 2018
Last update posted
Jul 4, 2019

2015 – 2018

United States locations

U.S. sites
9
U.S. states
2
U.S. cities
6
Facility City State ZIP Site status
Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix Phoenix Arizona 85006
St Josephs Hospital and Medical Center - Center for Liver Disease and Transplantation - Phoenix Phoenix Arizona 85013
Mayo Clinic, Phoenix - Infectious Diseases Phoenix Arizona 85054-4502
Mayo Clinic, Scottsdale - Infectious Diseases Scottsdale Arizona 85259-5452
The University of Arizona - Banner University Medical Center Tucson Campus - Tucson Tucson Arizona 85724-0001
Kaiser Permanente Chester Avenue Medical Offices - Pulmonology Bakersfield California 93301
Kern Medical Center - Medicine Bakersfield California 93306-4018
UCSF Fresno Center for Medical Education and Research - Clinical Research Center Fresno California 93701
Kaiser Permanente Antelope Valley Medical Offices - Infectious Diseases Lancaster California 93534

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02663674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 4, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02663674 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →